SITE004-0167

SITE004 (DEU) › SITE004-0167

SITE004-0167

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2026-03-16

enrolled

AEs

5

Serious

0

Dropout signal

–

Adverse events

5

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-01-25 (study day 122); relationship: not assessed

mild assessed

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-11-28 (study day 64); relationship: not assessed

moderate assessed

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-10-30 (study day 35); relationship: NOT RELATED

moderate assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-28 (study day 33); relationship: not assessed

severe assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-17 (study day 22); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.